Bioray Biotech CoROCO:7561 83 Days Payable is 15.47 as of Dec. 2025, which is 47% below its 10-year median of 29.19. GuruFocus rates ROCO:7561 with a GF Score™ of 83/100 and a GF Value™ of NT$29.50 (Significantly Undervalued). Among 927 Drug Manufacturers companies, Bioray Biotech Co ranks worse than 97.2% on this metric.
The historical rank and industry rank for Bioray Biotech Co's Days Payable or its related term are showing as below:
ROCO:7561'
s Days Payable Range Over the Past 10 Years
Min: 11.55 Med: 29.19 Max: 40.98
Current: 15.2
During the past 9 years, Bioray Biotech Co's highest Days Payable was 40.98. The lowest was 11.55. And the median was 29.19.
ROCO:7561's Days Payable is ranked worse than 97.2% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs ROCO:7561: 15.20
Bioray Biotech Co's Days Payable
declined
from Dec. 2024 (24.19) to Dec. 2025 (15.47).
It may suggest that Bioray Biotech Coaccelerated paying its suppliers.
Bioray Biotech Co Days Payable Related Terms
Bioray Biotech Co Days Payable Historical Data
* Premium members only.
The historical data trend for Bioray Biotech Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bioray Biotech Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioray Biotech Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioray Biotech Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Bioray Biotech Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bioray Biotech Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioray Biotech Co (ROCO:7561) has a Days Payable of 15.47 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bioray Biotech Co and its competitors. This is 47% below median its historical median of 29.19. Over the past decade, Bioray Biotech Co's Days Payable has ranged from 11.55 to 40.98. According to the industry distribution chart, Bioray Biotech Co ranks #901 out of 927 companies in the Drug Manufacturers industry, placing it in the top 97.2%.
Is Bioray Biotech Co's Days Payable too high?
Bioray Biotech Co's current Days Payable of 15.47 is 47% below median its 10-year median of 29.19. Over the past 10 years, this metric has ranged from a low of 11.55 to a high of 40.98. The Drug Manufacturers industry median Days Payable is 90.38. Bioray Biotech Co's value of 15.47 is 82.9% below this industry median. Based on the distribution chart, Bioray Biotech Co ranks #901 out of 927 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bioray Biotech Co has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bioray Biotech Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bioray Biotech Co ranks #901 out of 927 companies for Days Payable. This places Bioray Biotech Co in the lower half of its industry. The industry median Days Payable is 90.38. Bioray Biotech Co's value of 15.47 is 82.9% below this benchmark. Historically, Bioray Biotech Co's own Days Payable has ranged from 11.55 to 40.98 over the past decade. While the company's 10-year median is 29.19 vs. the industry median of 90.38, Bioray Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioray Biotech Co's current Days Payable of 15.47 is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bioray Biotech Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioray Biotech Co's current Days Payable is 15.47, which is 47% below median its own 10-year median of 29.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioray Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Bioray Biotech Co (ROCO:7561) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$29.50, compared to a current price of NT$18.10 — trading 38.6% below its estimated fair value. The current Days Payable is 15.47, which is 47% below median its 10-year median of 29.19 and 82.9% below the Drug Manufacturers industry median of 90.38. Bioray Biotech Co's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bioray Biotech Co (ROCO:7561), the current Days Payable is 15.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioray Biotech Co (ROCO:7561) Overvalued in 2026?
Based on GuruFocus' analysis, Bioray Biotech Co stock appears to be undervalued.
The current stock price of NT$18.10 is trading 38.6% below its estimated GF Value™ of NT$29.50.
GuruFocus considers Bioray Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:7561:
Days Payable: 15.47 (47% below median its 10-year median of 29.19)
GF Value™: NT$29.50 vs. price of NT$18.10 (38.6% below fair value)
Industry Position: 82.9% below the Drug Manufacturers median (#901 of 927)
No single metric tells the full story. See the ROCO:7561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioray Biotech Co Ltd is engaged in the development and manufacturing of biological agents, including functional probiotics, medicinal fungi, and immune cell preparations.
83GF Score
Get the complete analysis for ROCO:7561
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7561 has been successfully added to your 
